Phase II study of high-dose cyclophosphamide in relapsing and/or resistant hepatoblastoma in children: a study from the SIOPEL group

Up‐regulation of breast cancer resistance protein expression in hepatoblastoma following chemotherapy: A study in patients and in vitro

“…However, some HBs are resistant to this or other chemotherapeutical regimens 6,7 . As a result, the tumor load decreases little or not during chemotherapeutic treatment of these HBs, rendering surgical treatment more difficult or even impossible.…”

Imaging recommendations for malignant liver neoplasms in children

“…This approach minimizes patient radiation exposure. Because the incidence of tumor recurrence remains low for more than 30 months after initial diagnosis, we recommend that patients who show no evidence of recurrent disease undergo follow‐up ultrasound imaging of the abdomen and plain film chest radiography rather than CT or MRI beginning at 2.5 years after diagnosis 29–31. The role of positron emission tomography (PET) and PET/CT in the management of pediatric liver tumors is yet to be established but may prove to be valuable in the evaluation of these patients.…”

Docetaxel in the Treatment of Children With Refractory or Relapsed Hepatoblastoma

“…SIOPEL has recently completed a phase II trial of irinotecan in refractory and relapsed HB, however, to date the results of published phase II studies involving patients with HB have yielded disappointing results. [6][7][8] Paclitaxel, a taxane, is active against HB in animal studies. 9 We report on our experience of using a related taxane, docetaxel in children with refractory HB.…”